"DAWN OF A NEW ERA!"

[stanleyock]

To: Geron Corporation
Attn: Ms. Dawn C Bir, Interim President & CEO
Attn: Ms. Elizabeth G.O'Farrell, Chair, Board of Directors

Dear Ms.Bir and Ms. O'Farrell,

We would like to extend our warmest welcome to both of you in your new roles as Interim President & CEO and Chair of the Board of Directors at Geron Corporation. As retail investors, we are optimistic that your leadership and experience will carry much-needed stability to Geron during this critical time, especially in the wake of the departure of Mr. John Scarlet after his 14 years of service. We recognize the humongous challenge of navigating through such a transition, but we are confident that with your guidance, Geron will embark on a new chapter of growth and success.

However, there is an urgent and longstanding issue that we, as retail investors, must bring to your immediate attention - the persistent and troubling manipulation of Geron’s stock price. This issue has plagued the company for years, and we believe it has significantly contributed to the recent sharp and ridiculous declines in stock value since the successful FDA approval of Imetelstat in Jun’24. The collapse in stock price following the 4th Quarter 2024 earnings call on 26 Feb’25 and the record trading volume only highlight the extent of this issue. We strongly feel that there is a concerted effort to drive down and suppress Geron’s stock, which we believe is detrimental not only to the company’s reputation and financial well-being but also to the long-term interests of its shareholders.

For decades, retail investors like ourselves have watched in frustration as the true value of Geron has been unfairly suppressed by this "elephant in the room." This issue has been met with radio silence and relative inaction from previous leadership teams and it remains a lingering concern for of us as shareholders. We can no longer accept the status quo of this deplorable situation, and we are now looking to you both to lead with urgency in addressing and dismantling this blatant ongoing manipulation once and for all.

We respectfully urge you to take immediate and decisive action to investigate the root causes of this stock suppression, and implement measures to ensure that such behavior be deterred and not condoned. The market has shown that Geron’s fundamentals are strong, and its future prospects are increasingly promising, now with EMA approval in the bag. However, without addressing this manipulation and ensuring fair market behaviour and a fair level playing field, Geron’s true potential will remain stifled, and investor confidence will continue to erode.

As we move forward, we trust that you will see it as a priority to restore the confidence among investors and shareholders, by ensuring that Geron’s stock value is aligned to its actual performance and long-term prospects. This is a critical moment for Geron, and we believe that under your leadership, Geron can emerge from this issue stronger than ever, with renewed trust and confidence from its investors and the market at large. Stock and company performance are not mutually exclusive.

Once again, we welcome both of you to your new roles and look forward to seeing your leadership bring much-needed change and progress to Geron. We remain committed to supporting the company and its leadership, but we urge you to take swift action in addressing the elephant in the room that has dogged Geron’s stock for far too long.

We, small retail long investors hail the “Dawn Of A New Era!”

Sincerely,

Poor and long suffering Retail Investors
StanleyRock – Singapore
P.S. Guys plse chip in and add in yr voice and sign off to officially send a letter to Geron. Dr. Jay can you see to this?

[Zhears]

Excellent letter.
I hope that you get an effective response. If not, why do none of the analysts in the calls ever raise this issue?

[biopearl123]

Stanley rock nice letter! Am on the road to Kansas City and will post something from “Errol” once I get settled.

[jayfish101]

Thank you Stanley! Great letter. I will write one myself today.
DR. J

[mistergern]

Great letter, Stanley. I can't wait to hear their response. The Jackals are at it again today. The manipulation begins a half hour after trading starts and is algorithmically manipulated for the remainder of the trading session. Occasionally, big volume buys push the price up temporarily, but when the buy volume diminishes, there is a concerted effort to step down the pps.

[jayfish101]

Attn: Ms. Dawn C Bir, Interim President & CEO
Attn: Ms. Elizabeth G.O'Farrell, Chair, Board of Directors

Dear Ms.Bir and Ms. O'Farrell,

I have been an investor in Geron for about twenty-five years and now hold over 350,000 shares. I have become increasingly concerned about the low share price, given what seems to be a plethora of recent good news. I wonder, as do many of my fellow shareholders, if there is a need to explore illegal price manipulation. I also wonder if there is some significant news that retail investors do not know. I hope that the new leadership will be more aggressive in pursuing these issues. I also hope there will be more transparency for investors.
I welcome both of you to your new roles and look forward to seeing your leadership bring much-needed change and progress to Geron. I hope I can remain committed to supporting the company and its leadership, but I urge you to take swift action in addressing the issues that have depressed Geron’s stock price far too long. My fellow investors on Imetelchat and I look forward to your response.
Thank you for your attention,
Dr. J

[stanleyock]

Finally a belated acknowledgement. Take comfort that it has been escalated. We shall see.

Hi Aron / Kristen

It has now been over 3 weeks since we raised serious concerns regarding the persistent and blatant manipulation of Geron’s stock price. Yet, we have not received so much as an acknowledgment from Investor Relations. This lack of response is not only deeply disappointing but also raises serious concerns about transparency and accountability.

Investor Relations exists to facilitate communication between shareholders and management. Silence is not an option. Retail investors, who have stood by Geron despite years of stock suppression, deserve a clear response. At this point, we demand to know:
• Has our appeal been escalated to Ms. Dawn C. Bir (Interim CEO) and Ms. Elizabeth G. O’Farrell (Chair, Board of Directors)?
• If so, when can investors expect an official response?
• If not, why has IR failed to escalate a matter that directly impacts shareholder value and corporate integrity?

We, Retail investors expect at minimum a formal acknowledgment and reassurance that leadership takes this matter seriously. Continued silence will only further erode trust and confidence in Geron’s governance.


Warmest regards


StanleyRock - Singapore
c/o Imetelchat Board



Hello –

Received and escalated.

Kristen Kelleher
Associate Director, Investor Relations & Corporate Communications
Geron Corporation
Email: kkelleher@geron.com

[kmall]

Great follow up letter StanleyRock. At least you elicited somewhat of a response, albeit vague at best. Thanks to you and all other I-Chat members who are taking action to facilitate a response from this company. Sad that it has come to the point where we need to pry answers from management on performing what is basically their jobs. BTW - IR recently added another high paying position. I guess having two there who basically do nothing wasn't enough. -Kmall

[biopearl123]

Stanleyrock, thanks for leading the charge on this. With the recent and abrupt change in leadership, I am surprised also that a special shareholders letter was not proffered. While trying to maintain a “business as usual” approach, (also know as silence), it is certainly not reassuring to shareholders. There are a lot of leading or misleading hires for positions I have never fathomed e.g. line extension. Knowing the long term vision and where therapies will expand would be helpful.

[Ryan]

Agree - $850 Million company now, so there now seem to be major question marks about the viability of the product in market. I think they should speak with their financial reports and guidance (eg show me the money) but the imbalance between the forecasted sales for Rytelo and the value of the kit and kaboodle company is a major disconnect, so something has got to give. Let’s see the cards (Revenue and revised Forecasting) and see, not silence.

[Ryan]

Stanleyrock, thanks for leading the charge on this. With the recent and abrupt change in leadership, I am surprised also that a special shareholders letter was not proffered. While trying to maintain a “business as usual” approach, (also know as silence), it is certainly not reassuring to shareholders. There are a lot of leading or misleading hires for positions I have never fathomed e.g. line extension. Knowing the long term vision and where therapies will expand would be helpful.

Proxies filed - Letter to Stockholders from Ms. Bir, with the Annual Report… checking it all out now…

[biopearl123]

Best way to make our (meager) voices heard is to wait until May 8th to cast our votes as a unit. A side note is that Geron is telegraphing the anticipated MF data but can't say anything (see next post).

[stanleyock]

Will not attend the virtual meet but shall navigate thru my broker here to cast my vote. Am continue my unflinching pursuit direct this time instead of thru IR given my follow up query on when can we expect an official reply upon their superficial response evokes not surprisingly the deafening sound of silence.

Date: 10 Apr’25
To: Geron Corporation
Attn: Ms. Dawn C. Bir, Interim President & CEO
Attn: Ms. Elizabeth G. O'Farrell, Chair, Board of Directors

Dear Ms. Bir and Ms. O'Farrell,

Congratulations to both of you on your new leadership roles in Geron. As retail investors, we welcome your expertise with great hope during this critical time, especially in the wake of Dr.John C. Scarlett’s departure after 14 years of service. While we recognize the challenges of transitioning leadership, we believe Geron now stands at a pivotal moment for bold and transparent governance.

However, one urgent matter requires immediate attention: the ongoing, blatant manipulation of Geron’s stock price. Despite FDA and EMA approvals, and with revenues flowing in, the stock has inexplicably plunged to dangerously low levels—suggesting not a rational market response, but a concerted, unchecked effort to suppress value.

The collapse after the Q4 2024 earnings call on Feb 26,2025, and the record trading volume thereafter, is not coincidental. These moves reflect a calculated strategy—potentially by parties profiting through short positions at the expense of long-term investors. This issue has gone unaddressed for far too long.

We urge you to take this matter seriously and recommend leveraging the expertise of Lisa Meletta, recently employed by Geron and formerly a U.S. Attorney experienced in prosecuting similar cases. Her presence gives Geron the tools to investigate and potentially halt these market abuses.

Despite solid fundamentals and $503M in cash, the market treats Geron like a pre-clinical startup.
Consider this comparison as of 17 Mar’25:
• Verona Pharma, whose drug was approved around the same time as Imetelstat (June 2024), has seen its stock skyrocket from $15 to $70.
• Geron, in contrast, has fallen from a high of $5.34 to $1.76, reminiscent of the post-Janssen fallout in 2018.
• Both companies reported quite similar Q4 revenues: Geron at $47.5M, Verona at $36.6M and yet, the market has moved in opposite directions.
• Verona cash at end Dec’24 $400M compared to Geron $503M

This stark discrepancy demands answers. It is not a retail phenomenon—it smells of coordinated manipulation, and we urge the Board to escalate this to the SEC for independent investigation.

Additionally, there is a worrying lack of transparency in how the company communicates. Retail investors are left to scour public forums and parse crumbs from scattered updates. Vital matters such as the EMA process delays, Anil's unexplained departure, or the prolonged MF trial timelines remain unaddressed.

Why are such material developments not proactively communicated? We are not just investors—we are stakeholders whose capital has funded the journey to this juncture.

We urge the following actions:
1. A formal investigation into suspicious trading patterns, both pre- and post-earnings.
2. Improved transparency and timely updates on key operational and regulatory milestones.
3. Open acknowledgment of shareholder concerns, rather than silence or vague IR replies.
4. A public stance against manipulation and an actionable plan to protect shareholder value.

And as we speak or should I say write, the stock is inching precariously to sub 1$ level which would trigger delisting threats from the Nasdaq and potentially force a reverse stock split—an outcome that destroys shareholder confidence, damages perception, and hurts ALL stakeholders, including institutional holders, employees, and potential partners.

The idea that a company with an FDA-approved product, revenue-generating operations, and global market ambitions could be staring down this deplorable path is both surreal and unacceptable.

Again this is not just a retail issue. If management and the Board continue to remain passive, they risk catastrophic long-term damage to the company’s credibility, investor trust, and overall market positioning. The time to act decisively is now—not after a reverse split becomes inevitable.

The time for passive tolerance has passed. We have waited, supported, and endured. Now, we need leadership with courage and clarity.

The "Dawn of a New Era" must be more than a catchphrase—it must embody fairness, transparency, and shareholder respect.

Sincerely,

Long-Suffering Retail Investors
StanleyRock – Singapore
c/o Imetelchat

[biopearl123]

Stanleyrock, thank you for writing that excellent letter that encapsulates our accumulating frustrations. There seemed to be an “I’m in charge now” voice in Ms. Bir’s letter but no new or reassuring information. There certainly was some shade cast in Dr. Scarlett’s direction regarding who might be best suited to take the company forward. Not a lot of recognition for past service. John is to use his words, “in the rear view mirror” but we shareholders appear to be under the tires. If fortune indeed now favors the bold, now is the time. Your letter was highly professional and your efforts appreciated. May 7th will be telling. We need updates on sales (naturally) as well as the ongoing programs. But we also need to know future directions: oral agent (smoke and mirrors or real), B cell disease, AML. The EHA presentations will need to be very strong. Fortunately there is money in the bank but also a big load of debt. I can only hope we will be shown inspired forward looking leadership going forward.